Evidence map›Paper›PMID 39237601›Full record

ArticleScientific reports2024

Preclinical modeling of metabolic syndrome to study the pleiotropic effects of novel antidiabetic therapy independent of obesity.

Jonathan P Mochel, Jessica L Ward, Thomas Blondel, Debosmita Kundu, Maria M Merodio, Claudine Zemirline, Emilie Guillot, Ryland T Giebelhaus, Paulina de la Mata, Chelsea A Iennarella-Servantez and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jonathan P MochelPrecision One Health Initiative, Department of Pathology, University of Georgia College of Veterinary Medicine, 501 D.W. Brooks Drive, Athens, GA, 30602, USA. jpmochel@uga.edu.
Jessica L WardVeterinary Clinical Sciences, Iowa State University, Ames, IA, 50011-1250, USA.
Thomas BlondelCeva Santé Animale, 33500, Libourne, France.
Debosmita KunduSMART Pharmacology, Iowa State University, Ames, IA, 50011-1250, USA.
Maria M MerodioVeterinary Clinical Sciences, Iowa State University, Ames, IA, 50011-1250, USA.
Claudine ZemirlineCeva Santé Animale, 33500, Libourne, France.
Emilie GuillotCeva Santé Animale, 33500, Libourne, France.
Ryland T GiebelhausThe Metabolomics Innovation Centre, Department of Chemistry, University of Alberta, T6G 2G2, Edmonton, Canada.
Paulina de la MataThe Metabolomics Innovation Centre, Department of Chemistry, University of Alberta, T6G 2G2, Edmonton, Canada.
Chelsea A Iennarella-ServantezSMART Pharmacology, Iowa State University, Ames, IA, 50011-1250, USA.
April BlongVeterinary Clinical Sciences, Iowa State University, Ames, IA, 50011-1250, USA.
Seo Lin NamThe Metabolomics Innovation Centre, Department of Chemistry, University of Alberta, T6G 2G2, Edmonton, Canada.
James J HarynukThe Metabolomics Innovation Centre, Department of Chemistry, University of Alberta, T6G 2G2, Edmonton, Canada.
Jan SuchodolskiGastrointestinal Laboratory, Texas A&M University, College Station, TX, 77845, USA.
Asta TvarijonaviciuteInterdisciplinary Laboratory of Clinical Analysis (Interlab-UMU), Veterinary School, Regional Campus of International Excellence 'Campus Mare Nostrum', University of Murcia, Campus de Espinardo s/n, Espinardo, 30100, Murcia, Spain.
José Joaquín CerónInterdisciplinary Laboratory of Clinical Analysis (Interlab-UMU), Veterinary School, Regional Campus of International Excellence 'Campus Mare Nostrum', University of Murcia, Campus de Espinardo s/n, Espinardo, 30100, Murcia, Spain.
Agnes Bourgois-MochelPrecision One Health Initiative, Department of Pathology, University of Georgia College of Veterinary Medicine, 501 D.W. Brooks Drive, Athens, GA, 30602, USA.
Faiez ZannadUniversité de Lorraine, Centre d'Investigations Cliniques Plurithématique 1433 and Inserm U1116, CHRU Nancy, FCRIN INI-CRCT, 54000, Nancy, France.
Naveed SattarSchool of Cardiovascular and Metabolic Health, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, Scotland, UK.
Karin AllenspachPrecision One Health Initiative, Department of Pathology, University of Georgia College of Veterinary Medicine, 501 D.W. Brooks Drive, Athens, GA, 30602, USA.

Funding

CEVA Sante Animale PO1126151
6 · The paper itself

Abstract

Cardiovascular-kidney-metabolic health reflects the interactions between metabolic risk factors, chronic kidney disease, and the cardiovascular system. A growing body of literature suggests that metabolic syndrome (MetS) in individuals of normal weight is associated with a high prevalence of cardiovascular diseases and an increased mortality. The aim of this study was to establish a non-invasive preclinical model of MetS in support of future research focusing on the effects of novel antidiabetic therapies beyond glucose reduction, independent of obesity. Eighteen healthy adult Beagle dogs were fed an isocaloric Western diet (WD) for ten weeks. Biospecimens were collected at baseline (BAS1) and after ten weeks of WD feeding (BAS2) for measurement of blood pressure (BP), serum chemistry, lipoprotein profiling, blood glucose, glucagon, insulin secretion, NT-proBNP, angiotensins, oxidative stress biomarkers, serum, urine, and fecal metabolomics. Differences between BAS1 and BAS2 were analyzed using non-parametric Wilcoxon signed-rank testing. The isocaloric WD model induced significant variations in several markers of MetS, including elevated BP, increased glucose concentrations, and reduced HDL-cholesterol. It also caused an increase in circulating NT-proBNP levels, a decrease in serum bicarbonate, and significant changes in general metabolism, lipids, and biogenic amines. Short-term, isocaloric feeding with a WD in dogs replicated key biological features of MetS while also causing low-grade metabolic acidosis and elevating natriuretic peptides. These findings support the use of the WD canine model for studying the metabolic effects of new antidiabetic therapies independent of obesity.

Indexed as

Disease Models, AnimalHypoglycemic AgentsMetabolic SyndromeObesityAnimalsBiomarkersBlood GlucoseBlood PressureDogsFemaleMaleNatriuretic Peptide, BrainOxidative StressBiomarkersBlood GlucoseHypoglycemic AgentsNatriuretic Peptide, BrainCardiorenal metabolic diseasesMetabolic syndromeOne healthWestern diet

Identifiers

PMID39237601
PMCPMC11377553

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.